Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta is viewed favorably because its allogeneic, off-the-shelf NK-cell platform could overcome major autologous CAR-T constraints by lowering manufacturing complexity, improving access, and enabling scalable treatment with potentially less risk of CRS/ICANS. The core investment case is strengthened by improving Ntrust-1/2 enrollment after 2026 protocol amendments, with initial data expected in 2H26 from at least 6 patients at the 4B dose and possible support for registrational development in autoimmune disease. Financially, the thesis is backed by an estimated $208M in YE:26 cash and modeled peak sales potential of $2.9B in lupus nephritis, while the broader pipeline is supported by favorable competitive and regulatory precedent.

Nkarta is facing a weak fundamental setup because 2Q26 operating expenses rose 40% sequentially to $43.1M, above expectations, while EPS remained deeply negative at ($0.54), underscoring persistent cash burn without commercial revenue. Although the company had $243.2M in cash and equivalents, funding needs are still substantial, with roughly $700M in additional financing assumed through 2040 and a runway only into 2028 versus company guidance into 2029. Its investment case is further burdened by early-stage clinical risk, competition in LN, no approved NK cell therapies to validate the category, and the possibility that safety, efficacy, regulatory, or financing setbacks could derail value creation.